Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

Crommelin, Heleen A.; Burg, Leone M. van der; Vorselaars, Adriane D.M.; Drent, Marjolein; Moorsel, Coline H.M. van; Rijkers, Ger T.; Deneer, Vera H.M.; Grutters, Jan C.

doi:10.1183/13993003.congress-2016.pa820

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Es wird diskutiert, dass Adalimumab bei der Behandlung von Sarkoidose weniger wirksam ist als Infliximab 36 . Das Medikament kann eine wirksame Alternative sein, wenn ein Patient eine systemische Reaktion auf Infliximab entwickelt 37 . Es wurde auch gezeigt, dass Etanercept, ein TNF-Rezeptorantagonist, eine geringere Ansprechrate aufweist als die Anti-TNF-Antikörper wie Infliximab 38 39 .…”

Section: Allgemeine Therapieempfehlungenunclassified

“…Cyclophosphamid (CYC) wurde zur Behandlung von refraktärer Neurosarkoidose verwendet 36 37 . Cyclophosphamid hat als Alkylans eine bekannte Toxizität, darunter Knochenmarksuppression, erhöhte Anfälligkeit für Infektionen, Einschränkung der Fertilität, hämorrhagische Zystitis, erhöhtes Malignitätsrisiko, insbesondere Urothelkarzinome, und selten Lungentoxizität 38 39 40 41 42 .…”

Section: Allgemeine Therapieempfehlungenunclassified

See 1 more Smart Citation

Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Skowasch,

Bonella,

Buschulte

et al. 2024

Pneumologie

View full text Add to dashboard Cite

ZusammenfassungDas vorliegende Positionspapier (AWMF) zur Therapie der Sarkoidose der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) wurde 2023 als deutschsprachige Ergänzung und Aktualisierung der internationalen Leitlinien der European Respiratory Society (ERS) aus dem Jahre 2021 verfasst. Sie enthält 5 im Konsensusverfahren abgestimmte Empfehlungen in Form von PICO-Fragen (Patients, Intervention, Comparison, Outcomes), die im Hintergrundtext der 4 Kapitel erläutert werden: Diagnosesicherung und Monitoring der Erkrankung unter Therapie, allgemeine Therapieempfehlungen, Therapie der Hautsarkoidose, Therapie der kardialen Sarkoidose.

show abstract

Section: Allgemeine Therapieempfehlungenunclassified

Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Skowasch,

Bonella,

Buschulte

et al. 2024

Pneumologie

View full text Add to dashboard Cite

show abstract

“…In addition, a successful outcome-defined as a reduction in immunosuppressive therapy improvement in FVC of 5% or greater, improvement in 6 MWD (minute walking distance) of 50 m or greater-was observed in 9/11 patients (82%) and 8/10 patients (80%) at weeks 24 and 52, respectively. In addition, among 18 patients who switched from infliximab to adalimumab due to antibody formation or severe adverse events, seven (39%) experienced clinical improvement, six (33%) remained stable, and five (28%) deteriorated [93]. Severe adverse events occurred in four patients, including one who discontinued adalimumab due to a lupus-like reaction.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art

Polverino

Balestro

Spagnolo

2020

JCM

View full text Add to dashboard Cite

Sarcoidosis is a systemic disease of unknown etiology characterized by the presence of noncaseating granulomas that can occur in any organ, most commonly the lungs. Early and accurate diagnosis of sarcoidosis remains challenging because initial presentations may vary, many patients are asymptomatic, and there is no single reliable diagnostic test. Prognosis is variable and depends on epidemiologic factors, mode of onset, initial clinical course, and specific organ involvement. From a pathobiological standpoint, sarcoidosis represents an immune paradox, where an excessive spread of both the innate and the adaptive immune arms of the immune system is accompanied by a state of partial immune anergy. For all these reasons, the optimal treatment for sarcoidosis remains unclear, with corticosteroid therapy being the current gold standard for those patients with significantly symptomatic or progressive pulmonary disease or serious extrapulmonary disease. This review is a state of the art of clinical presentations and immunological features of sarcoidosis, and the current therapeutic approaches used to treat the disease.

show abstract

“…After switching to adalimumab 39% of patients achieved clinical improvement and 33% stabilization. The typical dose for this agent is 40 mg every 1-2 weeks, intramuscularly [22,25].…”

Section: Adalimumabmentioning

confidence: 99%

Cardiac sarcoidosis – management and prognosis (RCD code: III-3A.3)

Błaut-Jurkowska

Kaźnica-Wiatr²,

Knap³

et al. 2017

Journal of Rare Cardiovascular Diseases

View full text Add to dashboard Cite

Sarcoidosis is a systemic, granulomatous disease of unknown etiology. Cardiac involvement in the course of sarcoidosis occurs in 5% of patients. However, about 25% of patient with systemic/pulmonary sarcoidosis might present with asymptomatic myocardial injury. The main manifestations of cardiac sarcoidosis are conduction abnormalities, ventricular arrhythmias and heart failure. Diagnosis of cardiac sarcoidosis remains a challenge for physicians. Treatment should be introduced at the time of diagnosis to prevent potentially lethal progression of cardiac disease. Steroids are the first drugs of choice. Additional anti-sarcoidosis agents are used as alternatives or to reduce the steroids dose. Some patients require implantation of a cardioverter-defibrillator for the prevention of sudden cardiac death. Patients with refractory ventricular tachyarrhythmia or severe, intractable heart failure unresponsive to optimal pharmacotherapy, require heart transplantation. Prognosis in cardiac sarcoidosis is highly variable, dependent on location and severity of heart involvement. This article reviews current diagnostic and therapeutic recommendations for cardiac sarcoidosis. JRCD 2017; 3 (2): 37-43

show abstract

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

Cited by 3 publications

References 0 publications

Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art

Cardiac sarcoidosis – management and prognosis (RCD code: III-3A.3)

Contact Info

Product

Resources

About